Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

12.2K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
12.2K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.

Nature communications·2026
Same author

Comprehensive multi-omic profiling of desmoplastic small round cell tumors identifies targetable pathways with therapeutic opportunities.

Molecular cancer research : MCR·2026
Same author

Nuclear export of R-loop by the DDX1 and XPO1 complex promotes senescence-associated secretory phenotype and inflammaging.

Nature aging·2026
Same author

Effector Vδ1 γδ T cells mediate anti-tumor immunity and are reprogrammed by imatinib in human gastrointestinal stromal tumor.

Research square·2026
Same author

Topical resiquimod elicits systemic protection and improves anti-PD1 therapy in melanoma via priming of CD8+ T cells.

Cancer immunology research·2026
Same author

Author Correction: The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.

Nature communications·2026

Related Experiment Video

Updated: Oct 22, 2025

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.5K

Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance.

Jianglan Liu1, Vito W Rebecca1,2, Andrew V Kossenkov1

  • 1Molecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania.

Cancer Research
|August 31, 2021
PubMed
Summary

Researchers identified a developmental LPAR1-axis crucial for neural crest-like stem cell (NCLSC) survival and melanoma cell resistance. Inhibiting LPAR1 enhanced targeted therapy efficacy and reduced melanoma invasion, revealing LPAR1 as a potential therapeutic target.

More Related Videos

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells
12:21

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells

Published on: March 3, 2016

10.6K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.1K

Related Experiment Videos

Last Updated: Oct 22, 2025

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

21.5K
Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells
12:21

Feeder-free Derivation of Melanocytes from Human Pluripotent Stem Cells

Published on: March 3, 2016

10.6K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.1K

Area of Science:

  • Oncology
  • Developmental Biology
  • Cell Biology

Background:

  • Metastatic melanoma presents significant clinical challenges, with frequent relapse despite targeted therapies for BRAF-mutant cases.
  • Intrinsically resistant melanoma cells exhibit properties of neural crest-like stem cells (NCLSCs), including invasiveness and self-renewal, contributing to therapeutic resistance.

Purpose of the Study:

  • To investigate shared transcriptional programs and vulnerabilities between NCLSCs and melanoma cells.
  • To identify novel therapeutic targets for overcoming melanoma resistance.

Main Methods:

  • Identification of a developmental LPAR1-axis.
  • Assessment of LPAR1 activity during melanoma progression and therapeutic resistance.
  • Genetic inhibition of LPAR1 to evaluate its impact on BRAFi ± MEKi efficacy, melanoma migration, and invasion.

Main Results:

  • A critical LPAR1-axis essential for NCLSC and melanoma cell survival was identified.
  • LPAR1 activity was found to increase with melanoma progression and acquired therapeutic resistance.
  • Genetic LPAR1 inhibition potentiated BRAFi ± MEKi efficacy and significantly reduced melanoma cell migration and invasion.

Conclusions:

  • LPAR1 is a novel therapeutic target for melanoma treatment.
  • Dissecting stem cell-like pathways, such as the LPAR1-axis, offers promise for overcoming melanoma therapy resistance and invasion.